Peter Wendell - Merck Independent Director
| MRK Stock | EUR 131.65 0.20 0.15% |
Director
Mr. Peter C. Wendell is Independent Director of the Company. He is Managing Director, Sierra Ventures since 1982 Faculty, Stanford University Graduate School of Business since 1991. Senior Advisor and Director, WestBridge Crossover Fund, LLC since 2011 Charter Trustee, Princeton University Chairman, Princeton University Investment Co. from 2003 to 2008 and Director from 1998 to 2008. Mr. Wendell was also a director of Merck Sharp Dohme Corporationration from 2003 to 2009. since 2003.
| Age | 68 |
| Tenure | 22 years |
Peter Wendell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Wendell against Merck stock is an integral part of due diligence when investing in Merck. Peter Wendell insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Wendell over a year ago Merck exotic insider transaction detected | ||
Peter Wendell over a year ago Acquisition by Peter Wendell of 270 shares of Merck subject to Rule 16b-3 |
Similar Executives
| Found 2 records | DIRECTOR Age | ||
| Chunlin Xin | CanSino Biologics | N/A | |
| ShouBai Chao | CanSino Biologics | 60 | |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Pamela Craig, Independent Director | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Patricia Russo, Independent Director | ||
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
| Rita Karachun, Senior Vice President - Finance, Global Controller | ||
| Christine Seidman, Independent Director | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Kathy Warden, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | ||
| Peter Wendell, Independent Director | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 87.36 B | |||
| Price To Book | 2.69 X | |||
| Price To Sales | 3.49 X | |||
| Revenue | 19.69 B | |||
| EBITDA | 5.96 B | |||
| Net Income | 3.06 B | |||
| Total Debt | 7.93 B | |||
| Cash Flow From Operations | 4.62 B | |||
| Price To Earnings To Growth | 3.00 X | |||
| Number Of Employees | 42 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.